Peptides Codex
ENFR
← Home
Research peptide

BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide studied in preclinical models of tissue repair and gastrointestinal protection. It is not an approved therapeutic in Canada or the United States.

By The Peptides Codex Editorial TeamReviewed July 10, 2026
Length
15 aa
Class
Research peptide
Function
Studied in tissue-repair and GI models
Context
Preclinical / research compound (not an approved drug in Canada/US)

Among the most searched research peptides — strong educational demand.

Also known as: Body Protection Compound-157 · BPC157 · PL 14736

Part of the Repair & recovery peptides cluster

Overview

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide studied in preclinical models of tissue repair and gastrointestinal protection. It is not an approved therapeutic in Canada or the United States.

Source & context

Biological / chemical source: Synthetic fragment related to gastric juice protein research

Primary research or clinical context: Preclinical / research compound (not an approved drug in Canada/US)

What researchers study

Published preclinical work has examined BPC-157 in models of soft-tissue injury, gut mucosal integrity, and angiogenesis-related pathways. Human clinical evidence remains limited relative to search interest.

Sequence and chemistry

The commonly cited sequence is GEPPPGKPADDAGLV. As a short linear peptide, it is typically discussed in the context of stability, formulation, and analytical identity (HPLC, MS) in research settings.

Why search volume is extreme

BPC-157 dominates research-peptide queries because recovery and gut-health narratives travel well on social media. Educational readers should separate viral claims from the size and quality of controlled human evidence.

Related compounds people compare

Common comparison and stacking searches pair BPC-157 with TB-500 and sometimes KPV. See our comparison guide for chemistry-level differences rather than protocol advice.

Analytical identity tips

When evaluating research materials, confirm the observed mass matches the theoretical mass of the free peptide (or stated salt form), review HPLC purity for that lot, and prefer COAs with chromatograms—not generic PDFs.

Regulatory context

In Canada and many other markets, products marketed for human injection without authorization are treated as unapproved drugs. This page is educational only and does not provide dosing or treatment advice.

Sequence

One-letter sequence commonly cited for BPC-157 (educational; isoforms and modifications may differ):

GEPPPGKPADDAGLV

GEPPPGKPADDAGLV

G1E2P3P4P5G6K7P8A9D10D11A12G13L14V15
Helical wheel projection

Residues plotted ~100° apart around an α-helix — clustering of one color reveals an amphipathic face.

Analyze sequences in the playground →

FAQ about BPC-157

What is BPC-157?+

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide studied in preclinical models of tissue repair and gastrointestinal protection. It is not an approved therapeutic in Canada or the United States.

Is BPC-157 an approved medicine?+

BPC-157 is discussed here as a research / educational topic. Preclinical / research compound (not an approved drug in Canada/US). This is not medical advice.

What is the typical length of BPC-157?+

BPC-157 is commonly described as approximately 15 amino acids (Research peptide).

Related peptides

TB-500
Research peptide
TB-500 refers to a synthetic peptide fragment associated with thymosin beta-4 research, studied for effects on cell migration and tissue remodeling in experimental models. It is not an approved medicine.
CJC-1295
Research peptide
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) studied for effects on the GH/IGF-1 axis. Variants with and without DAC (Drug Affinity Complex) appear in research discussions.
Ipamorelin
Research peptide
Ipamorelin is a selective growth hormone secretagogue receptor agonist peptide studied for GH release with a relatively focused receptor profile compared with earlier GHRPs.
Melanotan II
Research peptide
Melanotan II is a synthetic cyclic peptide that acts on melanocortin receptors. It has been researched in pigmentation and related pathways but is not approved for cosmetic tanning use.

References & further reading

  1. 1.Wikipedia — BPC-157
  2. 2.PubChem — compound summary for BPC-157 (CID 9941957)
  3. 3.Sikiric et al. (2014). Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des
  4. 4.Hsieh et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl)
  5. 5.Brcic et al. (2009). Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol
  6. 6.Cerovecki et al. (2010). Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res
  7. 7.Krivic et al. (2006). Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res
  8. 8.Krivic et al. (2008). Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone. Inflamm Res
  9. 9.Japjec et al. (2021). Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats. Biomedicines
  10. 10.Perovic et al. (2019). Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. J Orthop Surg Res
  11. 11.Mikus et al. (2001). Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns
  12. 12.Seiwerth et al. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol
  13. 13.Vuksic et al. (2007). Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. Surg Today
  14. 14.Sikiric et al. (2020). Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy. Curr Pharm Des
  15. 15.Sikiric et al. (2016). Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol
  16. 16.Vukojevic et al. (2022). Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res
  17. 17.Xu et al. (2020). Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol
  18. 18.Tian et al. (2023). Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS. Molecules
  19. 19.Sikiric et al. (2025). Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System. Pharmaceuticals (Basel)
  20. 20.Józwiak et al. (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel)
  21. 21.McGuire et al. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med
Disclaimer: Educational content only. Not medical advice. Not instructions for human use. Research peptides and unapproved products may be restricted or illegal to market for human consumption in your jurisdiction. Consult qualified professionals and applicable law.
You might also like: All peptides · Atlas · Research · Tools
Cite this: Peptides Codex — BPC-157 educational profile.
Tip: Use browser print (Ctrl/Cmd + P) for a clean PDF of this page.